- R&D Pipeline
- Season 2 (2021-2030)
| Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
|---|---|---|---|---|---|---|---|
| 1 | Phase 1 clinical development of TU7710, bypassing agent for hemophilia with prolonged half life. | ||||||
| Recombinant Protein | Haemophilia A, B | recombinant coagulation factor VIIa | Phase 1 | TiumBio Co., Ltd. | RS-2023-00282592 | ||
| 2 | Pre-clinical study and IND application of PAT101, a tophaceous gout treatment, using SelecAllTM technology | ||||||
| Recombinant Protein | Gout | Uric Acid | Preclinical | ProAbTech | RS-2023-00219125 | ||
| 3 | Development of Immunoferritin Cellem001 with Dual Immune Checkpoints Blockade and T/NK-tumor Cell Engager | ||||||
| Recombinant Protein | NSCLC, Melanoma | PD-L1, TIGIT | Preclinical | Cellemedy | RS-2023-00218402 | ||
| 4 | Phase 1 clinical trial of recombinant hyaluronidase ALT-BB4 | ||||||
| Recombinant Protein | N/A | Hyaluronidase | Phase 1 | Alteogen Inc. | HN22C0112 | ||